Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative mFOLFOX + Pembrolizumab in Resectable GEJ/Stomach Cancer
NCT03488667Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2018
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in adenocarcinoma of the gastroesophageal junction and gastric adenocarcinoma, sponsored by University of Kansas Medical Center. Primary endpoints: Pathological Response Rate and Number of Adverse Events related to toxicity up to 14 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
03
Conditions
adenocarcinoma of the gastroesophageal junctiongastric adenocarcinoma
Beyond the preview
Go deeper on NCT03488667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488667.